Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Hepatitis B Virus (HBV) is a hepadnavirus that is the principal pathogen underlying viral liver disease in human populations. In this study, we describe the isolation and characterization of a fully human monoclonal antibody for HBV. This HuMab was isolated by a combinatorial screen of the memory B-cell repertoire from an acute/recovered HBV-infected patient. Lead candidate selection was based upon strong binding and neutralizing activity for live HBV. We provide a detailed biochemical/biophysical, and subclass characterization of its specificity and affinity against all of the principal HBV genotypes combined with a functional analysis of its in vitro activity. We also demonstrate its potential as a prophylaxis/therapy in vivo using human liver chimeric mouse models for HBV infection. These data have important implications for our understanding of natural human immunity to HBV and suggest that this potentially represents a new antibody-based anti-viral candidate for prophylaxis and/or therapy for HBV infection.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586962 | PMC |
| http://dx.doi.org/10.1038/s41541-022-00516-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Type 1 regulatory cells suppress T-cell cytotoxicity to alleviate liver injury during acute hepatitis B virus infection in mice.
J Immunol
September 2025
Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, Qidong-Fudan Innovative Institution of Medical Sciences, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.
Hepatitis B virus (HBV) exclusively infects hepatocytes and produces large quantities of subviral particles containing its surface antigen (HBsAg). T cells play a central role in controlling HBV infection but can also mediate liver injury and contribute to disease progression. However, the mechanisms that regulate T-cell responses to eliminate the virus without causing immunopathology during acute HBV infection remain poorly defined.
View Article and Find Full Text PDFInteraction between W41 of the hepatitis B virus preS1 surface peptide and Y146/F274 of the cellular receptor molecule Na/taurocholate co-transporting polypeptide is essential for virus entry.
Mol Pharmacol
August 2025
Institute of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Biomedical Research Center Seltersberg, Justus Liebig University of Giessen, Giessen, Germany. Electronic address:
The myristoylated preS1 domain (myr-preS1) of the hepatitis B virus (HBV) large surface protein is essential for binding to the receptor protein, Na/taurocholate co-transporting polypeptide (NTCP), and for the subsequent internalization of the virus-receptor complex. NTCP, which is expressed in hepatocytes, plays a physiological role in hepatic bile acid transport. Recent cryo-electron microscopy structures of the myr-preS1-NTCP complex were used to analyze virus-receptor interactions at the molecular level.
View Article and Find Full Text PDFColloidal gold technology in viral diagnostics: Recent innovations, clinical applications, and future perspectives.
Virology
September 2025
Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, Xinjiang, China. Electronic address:
Colloidal gold technology has revolutionized viral diagnostics through its rapid, cost-effective, and user-friendly applications, particularly in point-of-care testing (POCT). This review synthesizes recent advancements, focusing on its role in detecting respiratory viruses, hepatitis viruses, and emerging pathogens. The technology leverages the unique optical and physicochemical properties of gold nanoparticles (AuNPs), including localized surface plasmon resonance (LSPR) and high surface-to-volume ratios, to achieve rapid antigen-antibody recognition with visual readouts within 15 min.
View Article and Find Full Text PDFRE: Prophylactic antiviral therapy and all-cause mortality in cancer patients with hepatitis B e antigen-negative chronic hepatitis B virus infection receiving immunosuppressive therapy.
J Natl Cancer Inst
September 2025
Department of Gastroenterology and Hepatology, Sincan Training and Research Hospital, Ankara, Turkey.
Navigating Hepatitis C care: Knowledge gaps and access barriers among young women who inject drugs in rural Appalachia.
PLoS One
September 2025
Wake Forest University School of Medicine, Department of Implementation Science, Winston-Salem, North Carolina, United States of America.
Background: Hepatitis C virus (HCV) and injection drug use among young women are dramatically rising in the rural United States. From 2004 to 2017, heroin use among non-pregnant women increased 22.4% biennially, mirroring increases in HCV cases, especially among younger populations.
View Article and Find Full Text PDF